Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8373474 | 0.86 | TDP1 (0.54) | KMT2AALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL587109 | 0.85 | LMNA (0.51) | HTTCTSDCA12CA1CA2 | |
| SCHEMBL29665304 | 0.85 | LMNA (0.51) | HTTCTSDCA12CA1CA2 | |
| SCHEMBL30852229 | 0.85 | G6PD (0.60) | HTTCTSDCA12CA1CA2 | |
| SCHEMBL148830 | 0.85 | G6PD (0.60) | HTTCTSDCA12CA1CA2 | |
| SCHEMBL1004686 | 0.83 | HSD17B10 (0.56) | CTSDCA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL7418150 | 0.83 | LMNA (0.50) | HTTCTSDCA12CA1CA2 | |
| SCHEMBL7066201 | 0.83 | CTSD (0.51) | HTTCTSDCA12CA1CA2 | |
| SCHEMBL264288 | 0.82 | IRAK4 (0.63) | HTTIRAK4CTSDCA12CA1 | |
| SCHEMBL29423358 | 0.82 | IRAK4 (0.63) | HTTIRAK4CTSDCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | VIVIDION THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2024182693-A1 | 2-AZASPIRO[3.3]HEPTANE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | VIVIDION THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | disclosed |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-10131640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2018-11-20 | — | — | US | disclosed |
| US-9475822-B2 | Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| CN-105859639-A | NOVEL ANTI-INFLAMMATORY AGENTS | 雷斯韦洛吉克斯公司 | 2016-08-17 | — | — | CN | disclosed |
| EP-0628032-B1 | QUINAZOLINONE ANTIANGINAL AGENTS | PFIZER LTD (GB) | 1998-05-13 | — | — | EP | disclosed |
| CN-1143358-A | Benzamide analogs, useful as parp (ADP-ribosyltransferase, ADRPT) DNA repair enzyme inhibitors | UNIV NEWCASTLE VENTURES LTD (GB) | 1997-02-19 | — | — | CN | disclosed |
| EP-0749415-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1996-12-27 | — | — | EP | disclosed |
| US-5482941-A | Quinazolinone antianginal agents | PFIZER INC. (US) | 1996-01-09 | — | — | US | disclosed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | disclosed |
| EP-0628032-A1 | QUINAZOLINONE ANTIANGINAL AGENTS | Pfizer Limited (GB) | 1994-12-14 | — | — | EP | disclosed |
| EP-0263523-B1 | Process for the preparation of thiazolo [2,3-b] quinazolones | BASF AG (DE) | 1993-12-29 | — | — | EP | disclosed |
| WO-1993012095-A1 | QUINAZOLINONE ANTIANGINAL AGENTS | PFIZER LIMITED (GB) | 1993-06-24 | — | — | WO | disclosed |
| US-5030727-A | Reacting an anthronilide derivative with a thiazole derivative or a fluorozuinazolone with a neucleophile | BASF AKTIENGESELLSCHAFT (DE) | 1991-07-09 | — | — | US | disclosed |
| EP-0263523-A2 | Process for the preparation of thiazolo [2,3-b] quinazolones | BASF Aktiengesellschaft (DE) | 1988-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | HTT 4509/4885IRAK4 90/4885CTSD 2621/4885 |
| US-10882828-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | HTT 4509/4885IRAK4 90/4885CTSD 2621/4885 |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | HTT 4509/4885IRAK4 90/4885CTSD 2621/4885 |
| US-10131640-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | HTT 4509/4885IRAK4 90/4885CTSD 2621/4885 |
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | STAT3, JAK2, STAT1 | HTT 2654/4885IRAK4 194/4885CTSD 3146/4885 |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | HTT 4528/4885IRAK4 78/4885CTSD 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.